Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 210 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Athyros, Vasilios G [Clear All Filters]
Lipoprotein-associated phospholipase A2 and arterial stiffness evaluation in patients with inflammatory bowel diseases..
J Crohns Colitis. 8(9), 936-44.
(2014). Metabolic syndrome and non-cardiac vascular diseases: an update from human studies..
Curr Pharm Des. 20(31), 4944-52.
(2014). Metabolic syndrome in clinical practice..
Cardiol J. 21(2), 209.
(2014). Novel data on the pathogenesis of atherosclerosis, treatment targets, and new therapeutic interventions in lipid-related cardiovascular risk factors..
Curr Pharm Des. 20(40), 6215-9.
(2014). Peripheral artery disease in patients with type 2 diabetes..
J Diabetes Complications. 28(6), 912.
(2014). The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]..
Expert Opin Drug Metab Toxicol. 10(6), 787-812.
(2014). Prehypertension and the cardiometabolic syndrome: targeting several risk factors to achieve maximum benefit..
Expert Rev Cardiovasc Ther. 12(3), 295-6.
(2014). Reaching hypertriglyceridemia goals..
Curr Med Res Opin. 30(3), 391-3.
(2014). The role of statins in the treatment of type 2 diabetes mellitus: an update..
Curr Pharm Des. 20(22), 3665-74.
(2014). Should we expand the concept of coronary heart disease equivalents?.
Curr Opin Cardiol. 29(4), 389-95.
(2014). Statin-fibrate combination therapy is safe and effective in normalizing lipid profile and in keeping cardiovascular event rates low..
Curr Med Res Opin. 30(1), 57-8.
(2014). Subclinical Cushing's syndrome and cardiovascular disease..
Lancet Diabetes Endocrinol. 2(5), 361.
(2014). Therapy: Caloric and fat intake in statin users..
Nat Rev Endocrinol. 10(8), 450-1.
(2014). Is there an association between inflammatory bowel diseases and carotid intima-media thickness? Preliminary data..
Angiology. 65(6), 543-50.
(2014). Treating heart failure with preserved ejection fraction: statins could make the difference..
Angiology. 65(4), 328-9.
(2014). Undertreatment of dyslipidemia: from the Arabian Gulf to the USA. Time to solve this problem!.
Curr Med Res Opin. 30(12), 2425-8.
(2014). Uric acid, chronic kidney disease and type 2 diabetes: a cluster of vascular risk factors..
J Diabetes Complications. 28(2), 122-3.
(2014). 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?.
Metabolism. 62(1), 21-33.
(2013). Alcohol consumption and the heart..
Int J Cardiol. 168(4), 4319.
(2013). Cardiovascular risk reduction with combination of anti-atherosclerotic medications in younger and older patients..
Curr Med Res Opin. 29(7), 791-2.
(2013). Cold temperature and cardiovascular mortality..
Circ J. 77(11), 2846.
(2013). Comment on: Novel therapeutic targets for non-alcoholic fatty liver disease..
Expert Opin Ther Targets. 17(7), 861-2.
(2013). Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property"..
Dig Liver Dis. 45(1), 82-3.
(2013). Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity..
J Clin Lipidol. 7(1), 88.
(2013).
(2013).